ABSTRACT
Background: The orphan status of sickle cell invites many researchers toward drug development in the past decade. A substantial number of clinical trials either understudies or in the planning stage focused on sickle cell disease. Sickle cell traits are often considered asymptomatic and the silent condition is associated with diverse complications. Objective: To clinically evaluate the safety and effectiveness of T-AYU-HM Premium Tablets (300mg) in sickle cell anemia patients: an observational retrospective study Methodology: This is a single-arm case-control retrospective study of sickle cell trait patients admitted to Dhanvantari Clinic from 2018 to 2020. Patients' vital and clinical information based on inclusion and exclusion criteria were collected and analyzed using SPSS software. Result: A total of 100 patients with sickle cell traits were included in the study. The treatment exhibited significant improvement was seen in (P<0.05) in hemoglobin and red blood corpuscles. There wasn’t any untoward response either from the patient or from laboratory parameters reported indicating no adverse effects were seen. There was an absolute improvement in overall health as a reduction of no of time hospitalization (0) and blood transfusion (0) in sickle cell trait patients. There was a significant improvement in minor and major clinical parameters of sickle cell trait patients. Conclusion: The effect of T-AYU-HM Premium treatment in sickle cell trait patients suggests it is safe and effective. There was no adverse effect observed in the observational study. During entire study period, no single blood transfusion or hospitalization required. The significant improvement in the rate and frequency of painful crises indicates an improvement in pain-related quality of life in patients. This treatment of T-AYU-HM Premium was safe, cost-effective, and exhibit therapeutic potential in the management of sickle cell trait patients
ABSTRACT
Hemiplegic stroke is one of the major prevalent mortality in many countries including India. In hemiplegic stroke spasticity, and muscle atrophy results in the inability to move certain muscles. Most post-stroke complications like inability and shoulder pain are a major concern for therapeutic interventions. Recent advances have been made in the interdisciplinary approach of rehabilitation, artificial intelligence, brain-computer interface, and much more mainly targeting post-stroke complications. In the present case report study 55-year-old male addicted to tobacco, altered HBA1c, elevated neutrophils, erythrocyte sedimentation rate, and C-reactive protein and CT scan report of mild cerebral atrophy suggestive of hemiplegic stroke. The patient was admitted on a stretcher with no sensation in his left hand and Vaksanga (impaired speech). After receiving the patient and family member's consent the integrated treatment was initiated. After 15 days of integrated treatment including T-AYU-HM Premium, significant improvement in the patient’s condition was noticed. The patient recovered from the impaired mobility of the left hand and remarkable improvement in slurred speech. This confirms that the intervention of Ayurvedic medicine in post-stroke management and prevention of stroke might play a crucial role. More such kinds of interventional case studies or trials should be warranted to justify the same.
ABSTRACT
Standard therapy for advanced ovarian cancer (OC) consists of radical debulking cytoreductive surgery followed by adjuvant chemotherapy. An important risk factor for OC is genetic predisposition, with BRCA1 or BRCA2 mutations accounting for the majority of hereditary OC. Mutation in BRCA ultimately causes accumulation of genetic alterations because of the failure of cells to arrest and repair DNA damage or to undergo apoptosis, resulting in tumorigenesis. Poly (ADP?ribose) polymerase (PARP) inhibitors have emerged as a promising approach for managing BRCA?associated cancers, especially high?grade OC and breast cancers. They lead to synthetic lethality in BRCA?mutated cells by stalling the replication forks in homologous recombination?deficient (HR) cells. Four PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) are currently approved by the Food and Drug Administration for OC, breast, and pancreatic cancer indications and are being evaluated for other BRCA?associated cancers. Despite their clinical efficacy, cancer cells generally develop resistance to them through several mechanisms. Understanding these mechanisms is crucial for developing strategies to counter resistance and identify the basic mechanisms of DNA damage response. This review focuses on the mechanism of action of PARP inhibitors, understanding various causes of resistance, and building strategies to overcome PARP inhibitor resistance
ABSTRACT
Pyogenic infection occurring in the pilonidal sinus is very common in young individuals with sedentary occupation. Tuberculous infection of pilodinal sinus is extremely rare and restricted to a case report in the literature. We present a 68-yearold male presenting with long standing pilonidal sinus with tuberculous infection.